Amprenavir: A New HIV Protease Inhibitor
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Amprenavir: A New HIV Protease Inhibitor
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1057
Article Code: 1057b
Date: July 16, 1999
Volume: 41
Pages: 63-66
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1057
Article Code: 1057b
Date: July 16, 1999
Volume: 41
Pages: 63-66
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)